The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events
- 1 February 2004
- journal article
- clinical trial
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 27 (2), 185-190
- https://doi.org/10.1016/j.jpainsymman.2003.06.010
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled TrialJournal of Clinical Oncology, 2001
- Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly DosingJournal of Clinical Oncology, 2001
- Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.Journal of Clinical Oncology, 1998
- A multicenter study of recombinant human erythropoietin (epoetin α) in the management of anemia in cancer patients receiving chemotherapyAnti-Cancer Drugs, 1997
- Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.Journal of Clinical Oncology, 1997
- Erythropoietin increases hemoglobin during radiation therapy for cervical cancerInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancerThe Lancet, 1994
- Erythropoietin for anaemia in cancer patientsEuropean Journal Of Cancer, 1993
- Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.Journal of Clinical Oncology, 1991
- Erythropoietin Treatment of Anemia Associated with Multiple MyelomaNew England Journal of Medicine, 1990